A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Dennis L. Citrin, Merrill S. Kies, Carl‐Bertil ‐B Wallemark, Jan Khandekar, Edward Kaplan, Fernando Camacho, Richard Lind

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

Original languageEnglish (US)
Pages (from-to)457-460
Number of pages4
Issue number3
StatePublished - Aug 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer'. Together they form a unique fingerprint.

Cite this